Abstract
We read with great interest the excellent review by Lee &Ansell on direct thrombin inhibitors recently published inthe British Journal of Clinical Pharmacology [1].We wouldbriefly comment on the reported dosage of lepirudin.Table1 of the review article displays the official lepirudindose,as provided by the summary of product characteris-tics and also indicated in the last edition of the ACCPguideline on parenteral anticoagulants [2], suggesting toadminister, in patients with heparin-induced thrombocy-topenia (HIT) and thrombosis, a bolus of 0.4mgkg
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
